In this review, we have elucidated the clinical trials and detailed mechanisms of anti-angiogenesis drugs in melanoma treatment, such as monoclonal antibodies (Bevacizumab, Ramucirumab, Aflibercept, Ontuxizumab), tyrosine kinase inhibitors (Sorafenib, Lenvatinib, Imatinib, Sunitinib, Pazopanib, Axitinib) and human recombinant Endostatin. Here, COL18A1 is linked to melanoma.